Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapidly progressive glomerulonephritis

W K Bolton1

  • 1Division of Nephrology University of Virginia Health Sciences Center, Charlottesville 22908, USA.

Seminars in Nephrology
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of the nephrologist in ESRD/Pre-ESRD care: a collaborative approach.

Journal of the American Society of Nephrology : JASN·2001
Same author

Pathogenesis of focal glomerulosclerosis.

Nephron·2001
Same author

ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.

Kidney international·2000
Same author

Intravenous iron dextran treatment in predialysis patients with chronic renal failure.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2000
Same author

Treatment of glomerular diseases: ANCA-negative RPGN.

Seminars in nephrology·2000
Same author

Improved urea reduction ratio and Kt/V in large hemodialysis patients using two dialyzers in parallel.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2000
Same journal

Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?

Seminars in nephrology·2026
Same journal

Proposed Role for Quantitative Podocyturia as a Clinical Marker of Systemic Endothelial Injury: Implications for Cardiovascular Disease and Longevity.

Seminars in nephrology·2026
Same journal

Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?

Seminars in nephrology·2026
Same journal

From Nephron Number to Global Health.

Seminars in nephrology·2026
Same journal

Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.

Seminars in nephrology·2026
Same journal

Of Diuretics, Transporters, and Mechanisms of Hypertension.

Seminars in nephrology·2026
See all related articles

Rapidly progressive glomerulonephritis (RPGN) is a severe kidney disease with a poor prognosis. Early diagnosis and aggressive treatment, utilizing current and emerging therapies, can significantly improve patient outcomes.

Area of Science:

  • Nephrology
  • Internal Medicine
  • Pathology

Background:

  • Rapidly progressive glomerulonephritis (RPGN) is a clinical syndrome characterized by rapid loss of kidney function.
  • RPGN has a historically poor prognosis without timely and aggressive intervention.
  • Understanding the diverse etiologies of RPGN is crucial for effective management.

Purpose of the Study:

  • To provide a diagnostic and therapeutic schema for various types of RPGN.
  • To outline the application of current diagnostic tools, including serological markers.
  • To address treatment selection, response assessment, and prognostic factors.

Main Methods:

  • Review of current literature and clinical guidelines.
  • Integration of diagnostic strategies (serological, immunological, histological).

Related Experiment Videos

  • Analysis of established and emerging therapeutic options.

    • Main Results:

    • A structured approach to RPGN diagnosis facilitates timely intervention.
    • Current therapies have demonstrated improvements in patient prognosis.
    • Emerging treatments hold further promise for managing this devastating condition.

    Conclusions:

    • Early and accurate diagnosis is paramount for improving RPGN outcomes.
    • Aggressive and tailored therapeutic strategies are essential for managing RPGN.
    • Ongoing research into novel therapies will further enhance treatment efficacy and patient prognosis.